Generation and Characterization of Functional Cardiomyocytes Derived from Human T Cell-Derived Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) have been proposed as novel cell sources for genetic disease models and revolutionary clinical therapies. Accordingly, human iPSC-derived cardiomyocytes are potential cell sources for cardiomyocyte transplantation therapy. We previously developed a novel generation method for human peripheral T cell-derived iPSCs (TiPSCs) that uses a minimally invasive approach to obtain patient cells. However, it remained unknown whether TiPSCs with genomic rearrangements in the T cell receptor (TCR) gene could differentiate into functional cardiomyocyte in vitro. To address this issue, we investigated the morphology, gene expression pattern, and electrophysiological properties of TiPSC-derived cardiomyocytes differentiated by floating culture. RT-PCR analysis and immunohistochemistry showed that the TiPSC-derived cardiomyocytes properly express cardiomyocyte markers and ion channels, and show the typical cardiomyocyte morphology. Multiple electrode arrays with application of ion channel inhibitors also revealed normal electrophysiological responses in the TiPSC-derived cardiomyocytes in terms of beating rate and the field potential waveform. In this report, we showed that TiPSCs successfully differentiated into cardiomyocytes with morphology, gene expression patterns, and electrophysiological features typical of native cardiomyocytes. TiPSCs-derived cardiomyocytes obtained from patients by a minimally invasive technique could therefore become disease models for understanding the mechanisms of cardiac disease and cell sources for revolutionary cardiomyocyte therapies.

[1]  Lior Gepstein,et al.  Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients. , 2013, European heart journal.

[2]  Philip Wong,et al.  Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.

[3]  Karl-Ludwig Laugwitz,et al.  Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Versatile Tool for Arrhythmia Research , 2013, Circulation research.

[4]  B. Knollmann,et al.  Induced Pluripotent Stem Cell–Derived Cardiomyocytes: Boutique Science or Valuable Arrhythmia Model? , 2013, Circulation research.

[5]  S. Yuasa,et al.  Novel insights into disease modeling using induced pluripotent stem cells. , 2013, Biological & pharmaceutical bulletin.

[6]  Euan A Ashley,et al.  Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.

[7]  Fred H. Gage,et al.  Induced pluripotent stem cells: the new patient? , 2012, Nature Reviews Molecular Cell Biology.

[8]  Takashi Daimon,et al.  Feasibility, Safety, and Therapeutic Efficacy of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Sheets in a Porcine Ischemic Cardiomyopathy Model , 2012, Circulation.

[9]  Shinsuke Yuasa,et al.  Disease characterization using LQTS-specific induced pluripotent stem cells. , 2012, Cardiovascular research.

[10]  Takashi Aoi,et al.  Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells , 2012, Proceedings of the National Academy of Sciences.

[11]  Euan A. Ashley,et al.  Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.

[12]  Ofer Binah,et al.  Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation , 2012, Journal of cellular and molecular medicine.

[13]  S. Baek,et al.  Perspectives on stem cell therapy for cardiac regeneration. Advances and challenges. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[14]  James W. Smyth,et al.  The gap junction life cycle. , 2012, Heart rhythm.

[15]  D. Malan,et al.  Cardiomyocytes Obtained From Induced Pluripotent Stem Cells With Long-QT Syndrome 3 Recapitulate Typical Disease-Specific Features In Vitro , 2011, Circulation research.

[16]  Stéphanie Boué,et al.  Methods for making induced pluripotent stem cells: reprogramming à la carte , 2011, Nature Reviews Genetics.

[17]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[18]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[19]  J. Itskovitz‐Eldor,et al.  Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells , 2009, Journal of cellular and molecular medicine.

[20]  I. Ishida,et al.  Direct generation of induced pluripotent stem cells from human nonmobilized blood. , 2011, Stem cells and development.

[21]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[22]  Shinsuke Yuasa,et al.  Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. , 2010, Cell stem cell.

[23]  R. Jaenisch,et al.  Reprogramming of human peripheral blood cells to induced pluripotent stem cells. , 2010, Cell stem cell.

[24]  S. Yamanaka Patient-specific pluripotent stem cells become even more accessible. , 2010, Cell stem cell.

[25]  G. Church,et al.  Reprogramming of T cells from human peripheral blood. , 2010, Cell stem cell.

[26]  E. Nuwaysir,et al.  Derivation of Induced Pluripotent Stem Cells from Human Peripheral Blood T Lymphocytes , 2010, PloS one.

[27]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[28]  Lior Gepstein,et al.  Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells , 2009, Circulation.

[29]  Shinsuke Yuasa,et al.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. , 2009, Biochemical and biophysical research communications.

[30]  Yunyu Zhang,et al.  Wnt3a‐Induced Mesoderm Formation and Cardiomyogenesis in Human Embryonic Stem Cells , 2009, Stem cells.

[31]  Sean P. Palecek,et al.  Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells , 2009, Circulation research.

[32]  S. Yuasa,et al.  Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era , 2008, Expert review of cardiovascular therapy.

[33]  Katsushi Tokunaga,et al.  HLA-haplotype banking and iPS cells , 2008, Nature Biotechnology.

[34]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[35]  M. Zaugg,et al.  Integration of calcium with the signaling network in cardiac myocytes. , 2006, Journal of molecular and cellular cardiology.

[36]  Norio Nakatsuji,et al.  Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage. , 2006, Biochemical and biophysical research communications.

[37]  P. Doevendans,et al.  Cardiomyocyte differentiation of mouse and human embryonic stem cells * , 2002, Journal of anatomy.

[38]  R. Jaenisch,et al.  Monoclonal mice generated by nuclear transfer from mature B and T donor cells , 2002, Nature.

[39]  L Gepstein,et al.  Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. , 2001, The Journal of clinical investigation.

[40]  D. Conner Mouse embryo fibroblast (MEF) feeder cell preparation. , 2001, Current protocols in molecular biology.